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In order to decrease the peri-implant bone loss during the life-time of the implant, oral use of anti-
osteoporosis drugs (like bisphosphonates) has been suggested.
In this study, bone remodeling parameters identified from clinical trials of alendronate were used to
simulate the effect of those drugs used after total hip arthroplasty on the peri-implant bone density.
Results of the simulation show that the oral administrated drugs increase bone density around the
implant and decreases, at the same time, the micromovements between the implant and the surrounding
bone tissue.
Incorporation of drug effect in numerical studies of bone remodeling is a promising tool especially to
predetermine safe bisphosphonate doses that could be used with orthopedic implants.
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INTRODUCTION
Cementless hip implants are frequently used in young
patients. However, failure rates can exceed 30% after 15
years for patients younger than 50 years old [1]. Clearly,
for this situation the long term performance of implants
has to be increased.
The main cause of implant failure is loosening following
osteolysis caused by a combination of stress shielding [2]
and of inflammatory reaction induced by wear particles
[3,4]. Besides the improvement of the material and wear
properties of the implant, biological aspects of peri-implant
bone remodeling should be investigated.
The efficiency of bisphosphonate in controlling
osteoporosis has been shown by many authors [5,6].
Supposing that the same mechanism is driving osteo-
porosis and peri-implant bone resorption, it was then
suggested to use bisphosphonate to control peri-implant
osteolysis [7]. This idea is currently tested in clinical
studies [8]. However, as two opposing effects are
competing, namely osteolysis due to the implant and
decreased bone resorption due to the bisphosphonate, the
systemic doses to be administered to control the peri-
implant bone density remained unknown.
In the present study, using an FEM approach, we
investigate the effect of systemic bisphosphonate treat-
ment following total hip arthroplasty (THA) on the
evolution of the peri-implant bone density.
MATERIALS AND METHODS
Model of Bone Remodeling
The developed bone remodeling model [9] takes into
account the bone inhomogeneity and bone transverse
isotropic symmetry by using two field variables: the
relative density f and the anisotropy tensor M. To relate
the bone adaptation to the mechanical stress environment,
the temporal evolution of the relative bone density
_f ¼ df=dt is linked to the mechanical stimulus c applied
to the bone by a piecewise linear evolution relation
(Fig. 1). The anisotropy tensor M is kept constant with
time. This hypothesis is justified by the fact that the time
period over which our model is running is short as
compared to the rate of variation of the anisotropy in
human bone [10]. In a period of 10 years, the anisotropy
changes about by 10% while our model is simulating
duration of about 1.5 years [11].
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Moreover, numerically, changes in time of the
anisotropy tensor did not significantly change the results,
but the constant tensor shortens the calculation time [12].
In long bones like the femur, the anisotropy tensor can be
considered as spatially constant.
An equilibrium zone, where bone neither resorbs nor
densifies is delimited by two threshold stimuli cr and cd.
vr and vd are the slopes of the resorption and densification
rates respectively versus c. The bone density adaptation
function is then determined by the four parameters which
are vr, cr, vd and cd (Fig. 1). The stimulus c was set to a
plastic yield stress [9], which is a way of measuring the
microdamage, since plastic deformations are needed to
create microcracks [12].
The equation describing the bone adaptation behaviour
in our model is [10]:
_f ¼
vrðc2 crÞ c , cr
0 cr # c # cd
vdðc2 cdÞ c . cd
8><
>>:
ð1Þ
Model of the Drug Effect
Drugs used to control the disease of bone metabolism, e.g.
bisphosphonate, affect the bone turnover [5]. We propose
to model the effects of bisphosphonate by affecting the
values of the resorption parameters Cr and vr. The
formation parameters Cd and vd are kept constant since
clinically and numerically, in a situation of peri-implant
osteolysis, they have only very small effects on the
temporal evolution of bone density or on bone properties.
In this description, we assume that bisphosphonate has no
effect on the bone formation parameters. This point has
been confirmed for alendronate [13].
Application to Hip Arthroplasty
Geometry and FEM
The three-dimensional geometry of a proximal femur was
reconstructed from CT scan slices obtained from a routine
clinical examination of a 70-year-old female patient. Use
of the data was approved by the patient. The implant was
numerically inserted under supervision of an orthopedic
surgeon. The initial bone density distribution corresponds
to the density distribution obtained by the CT-scan and can
be considered as the clinical situation immediately after
implant insertion. Then, a finite element model of the
bone-implant system was obtained with a 3D mesh
generator [14] from the CT scan slices.
The FE mesh was based on 8-node isoparametric
elements and consisted of 21,854 nodes and 8028
elements. At the distal end of the femur, the displacements
of the nodes were constrained. Each iteration took about
30 min of calculation on a Silicon Graphics Origin 2000,
using 1 out of 8 processors.
A discontinuous frictional contact between bone and
implant was included, allowing us to evaluate shear
micromotion between them. The used friction law was an
implementation of the Coulomb’s law. The friction
coefficient was 0.2. The implant’s surface was considered
as master surface and the bone’s surface as slave surface.
Every iteration corresponds to a different time step,
since the “step doubling” technique is used [9]. The
evolution equation was iteratively solved by custom-made
software REM [12] driving ABAQUS (Hibbitt, Karlsson, &
Sorensen Inc., Newpark, USA) analysis program.
The forces used to simulate muscle action on the head of
the implant have been experimentally determined
[15–17]:
Gluteus Maximus: 1901N
Gluteus Medius: 1237N
Psoas: 771N
Drug Application
In the present study, four concentrations of alendronate
treatment following THA were simulated: normal bone
remodeling (Cr and vr corresponding to placebo identified
values) and bone remodeling with 5, 10, 20 mg systemic
alendronate treatment (Cr and vr corresponding to 5, 10,
20 mg alendronate identified values).
The numerical values used for the normal bone
remodeling (corresponding to the placebo case) in this
study have been experimentally determined [12,18,19].
In these experiments, the authors measured the bone
mineral density in patients who had one limb immobilized
during convalence of a fracture. The bone mineral density
was also measured once the limb was bearing weight. This
results were then plotted versus time and loading history.
Therefore the numerical values identified are:
n placebor ¼ 2:800 week21 and c placebor ¼ 7:5 £ 1023
n placebor ¼ 0:805 week21 and c placebod ¼ 3:0 £ 1022
FIGURE 1 Bone relative density evolution in function of mechanical
stimulus.
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The numerical values for the bone remodeling
following alendronate treatment were obtained from a
theoretical work [20] based on a phase III clinical trial of
alendronate [6]. The parameters used in order to simulate
the effect of orally administrated alendronate are given in
Table I [20].
Results Visualization
In order to visualize the results, we define the mean
relative density (MRD) as the sum of the densities at all
the nodes of the considered part divided by the number of
nodes present in the considered part.
In order to visualize the effect of drug concentration on
the micromovement at the bone-implant interface, we
define the average interface micromovement (AIM) as the
sum of the norms of the interfaces micromovements
(movements between implant surface and inside bone
surface) at the bone-implant interface at all the nodes of
the interface divided by the number of nodes present in the
considered part. AIM is expressed in mm.
The MRD and AIM were reported according to the
grouped Gruen zones, defined as shown in Fig. 2.
RESULTS
The use of the parameters modeling the effect of
alendronate on bone remodeling increased the MRD by
2.5% for the 5 mg dose, 3.5% for the 10 mg dose and 4.0%
for the 20 mg dose as compared to the placebo case after
60 weeks when considering all Gruen zones (Fig. 3). At all
time, the peri-implant MRD is higher in the models that
were simulating alendronate treatment.
The simulated systemic alendronate treatment increases
the bone density in the whole femur in a dose dependent
manner when compared to the placebo case (Fig. 4). The
proximal femur (Gruen zones 1 and 7; see Table II), where
bone resorption takes place, experienced a smaller
resorption when alendronate presence is simulated than
in the placebo. The zones 2–6 also experience a higher
MRD but in a lesser extent. In the distal femur, where
densification takes place, the densification is only slightly
increased. The increase is dose dependent but the main
increase in MRD is between placebo and the 5 mg case.
The AIM at the bone implant interface is strongly
reduced in the cases where alendronate treated bone is
simulated. At equilibrium, the reduction is 62% and only
slightly dose dependent (Table III).
The strongest AIM decrease takes place in the proximal
femur, namely the Gruen zones 1, 2, 6 and 7 (Table IV).
The AIM decreases in the zones 3 and 5 is 10% lower than
the decreases in the zones 1, 2, 6 and 7. The AIM decrease
is only slightly dose dependent. The AIM in the
Gruen zone 4 is zero because no interface is present in
this zone.
DISCUSSION
There is a need to increase the lifespan of hip implants
especially for younger patients. For this purpose,
Shanbhag et al. [7] suggested the use of systemic
bisphosphonate treatment to inhibit wear debris osteolysis.
A canine THA model showed promising results. However,
the use of bisphosphonate bears the danger of side effects
(throat damage, ulcer) and undesired systemic skeletal
effects on bone remodeling.
Therefore, a minimal bisphosphonate dose must be
used. This dose will be a trade off between a sufficient
increase of the implant stability through the control of
bone remodeling control and minimal unwanted side
effects.
To evaluate the minimal dose, we used an existing
model developed by our group for calculation of bone
density around an implant during remodeling [9,21]
combined with bone remodeling parameters based on the
identification of data from clinical studies [20]. This tool
was used to simulate the effect of oral bisphos-
phonate treatment on the peri-implant bone density
following THA.
Our model showed that all three alendronate doses
decreased the peri-implant bone resorption but did not
suppress it, which is confirmed by clinical results obtained
by Wilkinson [8] in a clinical trial with pamidronate. The
trends and the shapes of the curves representing the
temporal evolution of the bone mineral density obtained in
the clinical study and with our model are the same.
By looking closer to the different zones and by adjusting
TABLE I Ratio of remodeling parameters used to simulate effect of oral
alendronate treatment on bone remodeling
Alendronate dose
Cxr
C placebor
mg
nxr
n placebor
mg
Placebo 1.00 1.00
5 mg 0.81 1.07
10 mg 0.75 1.17
20 mg 0.72 1.19
FIGURE 2 Gruen zones.
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the absolute values to relative values, we noticed that
the effect of the bisphosphonate measured in the clinical
study [8] and in our numerical study are of the same order
of magnitude. The differences between both studies can be
explained by different implant geometries, different initial
bone density distribution and differences between our
patient and the patients in the clinical study. The results
also showed that alendronate doses above 10 mg are only a
little more effective than doses below 10 mg, which is
confirmed by Libermann [6].
In this study, it has been assumed that alendronate
treatments had no effect on the bone formation
parameters. Experimentally, it has been observed that
beside resorption, formation may also decrease when
bisphosphonates was used [22]. Nevertheless, no
evidence for reduced osteoblastic activity at individual
bone formation sites was found. Specifically, effect of
alendronate on bone formation has not been observed
[13]. No adverse effects on bone structure or
mineralization was observed, alendronate preserved
the biomechanical properties of the bone.
Moreover, the variation of bone formation parameters
(clinically and numerically) has only a very small
influence on the bone remodeling around an implant
since most of the peri-implant bone is in resorption.
Since the equilibrium peri-implant bone distribution
is dependent on parameters like initial bone density or
type of implant, our model can be used to optimize the
dosage for a systemic alendronate treatment. Taking
into account these parameters, the goal would be to
FIGURE 3 Evolution of the mean density alendronate doses until equilibrium is reached (condition which stops the simulation).
FIGURE 4 Node by node difference between the relative densities in the placebo case and the three different alendronate doses cases.
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obtain the equilibrium density which gives the
longest possible service life of the implant with a
minimal risk for the patient due to side effects of
alendronate.
One of the reasons for the failure of hip arthroplasty is
osteolysis due to wear particles. A source of the wear
particles is the relative movement of the implant to the
surrounding bone. Moreover, micromovements between
the implant and the adjacent bone will lead to the
encapsulation of the implant by fibrous tissue. Therefore, a
very interesting point shown by this study is that
interfacial micromovements are diminished due to
bisphosphonate systemic treatment. The bisphosphonate
dose does not influence the micromovements like it does
influence the average bone density. This is probably due to
the fact that the micromovements are only influenced by
the bone very close to the implant surface, while the
average bone density is influenced by the whole bone.
Systemic bisphosphonate treatment would allow the
increase of the lifespan of the implant because the
alendronate treatment would allow to partially inhibit
the peri-implant bone resorption and the micromovements
at the bone-implant interface.
CONCLUSION
This study shows that the modification of the remodeling
behavior of bone in patients undergoing a bisphosphonate
treatment may allow to increase the lifespan of a hip
implant by decreasing the bone resorption and by
decreasing the micromovements at the bone-implant
interface. Therefore the evolution towards fibrous tissues
at the bone-implant interface would also be adverted [23].
Incorporation of drug effect in numerical studies of bone
remodeling is a promising tool especially to predetermine
safe bisphosphonate doses used in orthopedic implants in
order to increase the lifespan of the implant and the quality
of life of the patient.
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